Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have earned an average recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $4.75.
BDSI has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a report on Friday, July 6th. Zacks Investment Research upgraded BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a report on Monday, July 23rd. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $4.50 price objective on shares of BioDelivery Sciences International in a report on Thursday, August 9th.
In other news, Director Francis E. Odonnell, Jr. sold 151,039 shares of the company’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $2.84, for a total value of $428,950.76. Following the completion of the sale, the director now owns 520,482 shares in the company, valued at $1,478,168.88. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders sold 167,039 shares of company stock valued at $473,271. Insiders own 13.26% of the company’s stock.
Shares of BDSI stock opened at $3.78 on Thursday. The company has a quick ratio of 2.90, a current ratio of 3.16 and a debt-to-equity ratio of 1.21. BioDelivery Sciences International has a 1 year low of $1.70 and a 1 year high of $3.95. The firm has a market cap of $219.77 million, a price-to-earnings ratio of -9.69 and a beta of 0.63.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. BioDelivery Sciences International had a negative return on equity of 278.79% and a negative net margin of 103.01%. The company had revenue of $12.18 million during the quarter, compared to analyst estimates of $12.44 million. Equities analysts expect that BioDelivery Sciences International will post -0.61 EPS for the current year.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Featured Article: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.